PUBLISHER: The Business Research Company | PRODUCT CODE: 1947065
PUBLISHER: The Business Research Company | PRODUCT CODE: 1947065
Renal denervation devices represent minimally invasive medical solutions designed for the treatment of resistant hypertension cases unresponsive to conventional interventions. These devices involve the insertion of a catheter into the renal arteries, employing radiofrequency energy to ablate sympathetic nerves within the vessel walls. This process enhances blood flow to the kidneys.
Key products in the renal denervation devices market include the Simplicity Renal Denervation System, EnligHTN, Vessix Renal Denervation System, Iberis Renal Sympathetic Denervation System, Paradise Renal Denervation System, and others. The Simplicity Renal Denervation System, for instance, utilizes a catheter and generator to deliver radiofrequency energy to the renal nerves. Various technologies, such as radiofrequency ablation, ultrasound energy-based RDN, brachytherapy, chemical ablation, and others, are employed by these devices. Target end-users include hospitals, cardiovascular research centers, and other medical facilities.
Tariffs are impacting the renal denervation devices market by increasing costs of imported catheters, generators, ablation components, imaging accessories, and precision electronic parts used in minimally invasive systems. Hospitals and cardiovascular centers in North America and Europe are most affected due to dependence on imported medical devices, while Asia-Pacific faces pricing pressure on advanced interventional equipment. These tariffs are raising procedure costs and influencing procurement decisions. However, they are also encouraging localized manufacturing, regional supplier partnerships, and greater investment in domestic production of cardiovascular intervention devices.
The renal denervation devices market research report is one of a series of new reports from The Business Research Company that provides renal denervation devices market statistics, including renal denervation devices industry global market size, regional shares, competitors with a renal denervation devices market share, detailed renal denervation devices market segments, market trends and opportunities, and any further data you may need to thrive in the renal denervation devices industry. This renal denervation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The renal denervation devices market size has grown exponentially in recent years. It will grow from $0.74 billion in 2025 to $0.98 billion in 2026 at a compound annual growth rate (CAGR) of 32.5%. The growth in the historic period can be attributed to rising prevalence of resistant hypertension, advancements in catheter ablation technologies, increasing clinical research in renal denervation, expansion of interventional cardiology procedures, growing awareness of non-pharmacological hypertension treatments.
The renal denervation devices market size is expected to see exponential growth in the next few years. It will grow to $3.01 billion in 2030 at a compound annual growth rate (CAGR) of 32.4%. The growth in the forecast period can be attributed to increasing regulatory approvals for renal denervation devices, rising adoption in outpatient settings, growing demand for long-term hypertension management solutions, expansion of clinical evidence supporting efficacy, increasing investment in next-generation ablation systems. Major trends in the forecast period include increasing adoption of catheter-based hypertension therapies, growing use of radiofrequency and ultrasound ablation technologies, rising focus on minimally invasive cardiovascular interventions, expansion of image-guided renal denervation procedures, enhanced emphasis on procedure safety and precision.
The increasing prevalence of hypertension is expected to drive the growth of the renal denervation devices market. Hypertension, or high blood pressure, is a condition in which the force of blood against the walls of blood vessels remains consistently elevated. Renal denervation is a catheter-based, minimally invasive procedure developed as a potential treatment for patients with resistant hypertension that does not respond adequately to medication. For instance, in January 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, high blood pressure contributed to or directly caused 664,470 deaths in the United States in 2023. Therefore, the rising prevalence of hypertension is promoting demand for renal denervation devices.
Leading companies in the renal denervation devices market are concentrating on the development of ultrasound renal denervation (uRDN) to improve treatment effectiveness, minimize procedural complications, and offer a non-invasive alternative to conventional renal denervation methods. uRDN enhances renal denervation devices by facilitating precise, non-invasive energy delivery to the renal nerves, which effectively reduces blood pressure while safeguarding surrounding tissues, thereby increasing patient safety and comfort during the procedure. For example, in November 2023, Recor Medical Inc., a US-based medical technology firm, introduced the Paradise uRDN system, an innovative ultrasound renal denervation device aimed at treating hypertension in patients who have not reached blood pressure targets through standard lifestyle modifications and medications. This system incorporates hydrocooling technology to protect the renal artery during the procedure, marking a significant advancement in the renal denervation devices market by providing a novel, non-pharmacologic method for managing resistant hypertension and broadening treatment options for patients.
In May 2025, Boston Scientific Corporation, a US-based biotechnology and biomedical engineering firm, acquired SoniVie Ltd. for $360 million. Through this acquisition, Boston Scientific aims to expand its interventional cardiology portfolio by integrating SoniVie's TIVUS intravascular ultrasound system, an investigational device designed for renal artery denervation in hypertension treatment. SoniVie Ltd. is an Israel-based manufacturer specializing in renal denervation devices.
Major companies operating in the renal denervation devices market are Medtronic PLC, ReCor Medical Inc., Boston Scientific Corporation, Abbott Laboratories, Cordis Corporation, Terumo Corporation, Kona Medical Inc., St. Jude Medical LLC, Johnson & Johnson, Symple Surgical Inc., Cardiosonic Ltd., Mercator MedSystems Inc., Ablative Solutions Inc., Renal Dynamics Ltd., Vesalio LLC, Biotronik SE & Co. KG, Cook Medical LLC, Hansen Medical Inc., Merit Medical Systems Inc., AngioDynamics Inc., Covidien Ltd., Volcano Corporation
Europe was the largest region in the renal denervation devices market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global renal denervation devices market report during the forecast period. The regions covered in the renal denervation devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the renal denervation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The renal denervation devices market consists of sales of products including a single electrode, multi-electrode, irrigated catheter, and others. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Renal Denervation Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses renal denervation devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for renal denervation devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The renal denervation devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.